VIDEO: Port delivery system maintains improvements in diabetic retinopathy at 2 years
Click Here to Manage Email Alerts
In this Healio Video Perspective from the ASRS meeting, Margaret Chang, MD, MS, of Retinal Consultants Medical Group presents 2-year results for the port delivery system with ranibizumab.
The phase 3 Pavilion trial, involving 174 patients, investigated the platform for the treatment of nonproliferative diabetic retinopathy.
“PDS was able to maintain [Diabetic Retinopathy Severity Score] improvements achieved at year 1 through week 100 with 9-month refill intervals,” Chang said. “Patients who crossed over from the control group to PDS maintained or improved their DRSS score from baseline.”
Collapse
Chang M. Port delivery system with ranibizumab for continuous treatment in diabetic retinopathy: First readout of 2-year data from the phase 3 Pavilion trial. Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm.
Read more about
Click Here to Manage Email Alerts